CSF proteomics related to the neurovascular unit are associated with white matter hyperintensity volumes and cerebral microhemorrhages in autosomal dominant Alzheimer disease

Background Autosomal dominant Alzheimer disease (ADAD) is characterized by genetic mutations affecting the beta‐amyloid (Aß) pathway. However, vascular and immune factors play important roles which are not completely understood. Understanding the function of the neurovascular unit (NVU) comprised of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2024-12, Vol.20 (S9), p.n/a
Hauptverfasser: Joseph‐Mathurin, Nelly, Shen, Yuanyuan, Friedrichsen, Karl A., Chen, Charles D., McCullough, Austin A., Strain, Jeremy F., Shirzadi, Zahra, Chen, Gengsheng, Massoumzadeh, Parinaz, Gordon, Brian A., Llibre‐Guerra, Jorge J., Hassenstab, Jason J., Ibanez, Laura, Lu, Ruijin, Schultz, Stephanie A., Chhatwal, Jasmeer P., Morris, John C., Perrin, Richard J., An, Hongyu, Xiong, Chengjie, Klein, Robyn S., Jack, Clifford R., Bateman, Randall J., McDade, Eric, Benzinger, Tammie L.S., Cruchaga, Carlos
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Autosomal dominant Alzheimer disease (ADAD) is characterized by genetic mutations affecting the beta‐amyloid (Aß) pathway. However, vascular and immune factors play important roles which are not completely understood. Understanding the function of the neurovascular unit (NVU) comprised of neurons, glial cells, and vasculature, at different disease stages appears ideal to developing and evaluating therapeutics. Omics approaches can inform NVU changes and their disease associations. Methods CSF proteomic data using the Somalogic® platform was generated from 485 participants in the DIAN study, who also had PiB‐PET and MRI assessing Aß burden, white matter hyperintensity (WMH), and cerebral microhemorrhage (CMH). From previously published AD studies, we identified 33 NVU‐associated proteins with corresponding Somalogic aptamers (Figure 1). We used Principal Component Analysis (PCA) on participants with complete data (n = 262, 166 mutation‐carriers and 96 non‐carriers) to find groups of proteins associated with mutation status and disease stage as measured with estimated year to symptom onset (EYO), PiB‐PET, and clinical status. Linear‐mixed effect models and two‐part zero‐inflated negative binomial mixed models further evaluated the link between significant principal components (PCs) and WMH and CMH, respectively. Models accounted for age, APOE‐e4 status, sex, and education. Results The first ten PCs explained >60% of the variance in NVU‐related protein levels (Figure 2A) with only PC5 (4.8%) associated with mutation*EYO, suggesting relationship with ADAD‐specific disease progression (***p
ISSN:1552-5260
1552-5279
DOI:10.1002/alz.093619